Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 229 to 235 of 235 entries
Sorted by: Best Match Show Resources per page
Cryopyrin-Associated Periodic Fever Syndrome and the Nervous System.

Current treatment options in neurology

Keddie S, Parker T, Lachmann HJ, Ginsberg L.
PMID: 30175395
Curr Treat Options Neurol. 2018 Sep 03;20(10):43. doi: 10.1007/s11940-018-0526-1.

PURPOSE OF REVIEW: The purpose of this review is to highlight the molecular and clinical characteristics of the cryopyrin-associated periodic fever syndrome (CAPS) and its management. CAPS is an autosomal dominantly inherited autoinflammatory disorder associated with mutations in the...

Cite
Keddie S, Parker T, Lachmann HJ, et al. Cryopyrin-Associated Periodic Fever Syndrome and the Nervous System. Curr Treat Options Neurol. 2018;20(10):43doi: 10.1007/s11940-018-0526-1.
Keddie, S., Parker, T., Lachmann, H. J., & Ginsberg, L. (2018). Cryopyrin-Associated Periodic Fever Syndrome and the Nervous System. Current treatment options in neurology, 20(10), 43. https://doi.org/10.1007/s11940-018-0526-1
Keddie, Stephen, et al. "Cryopyrin-Associated Periodic Fever Syndrome and the Nervous System." Current treatment options in neurology vol. 20,10 (2018): 43. doi: https://doi.org/10.1007/s11940-018-0526-1
Keddie S, Parker T, Lachmann HJ, Ginsberg L. Cryopyrin-Associated Periodic Fever Syndrome and the Nervous System. Curr Treat Options Neurol. 2018 Sep 03;20(10):43. doi: 10.1007/s11940-018-0526-1. PMID: 30175395; PMCID: PMC6132776.
Copy Download .nbib Format: NLM
The TLR-4 agonist adjuvant, GLA-SE, improves magnitude and quality of immune responses elicited by the ID93 tuberculosis vaccine: first-in-human trial.

NPJ vaccines

Coler RN, Day TA, Ellis R, Piazza FM, Beckmann AM, Vergara J, Rolf T, Lu L, Alter G, Hokey D, Jayashankar L, Walker R, Snowden MA, Evans T, Ginsberg A, Reed SG.
PMID: 30210819
NPJ Vaccines. 2018 Sep 04;3:34. doi: 10.1038/s41541-018-0057-5. eCollection 2018.

Tuberculosis (TB) is the leading cause of infectious death worldwide. Development of improved TB vaccines that boost or replace BCG is a major global health goal. ID93 + GLA-SE is a fusion protein TB vaccine candidate combined with the...

Cite
Coler RN, Day TA, Ellis R, et al. The TLR-4 agonist adjuvant, GLA-SE, improves magnitude and quality of immune responses elicited by the ID93 tuberculosis vaccine: first-in-human trial. NPJ Vaccines. 2018;3:34doi: 10.1038/s41541-018-0057-5.
Coler, R. N., Day, T. A., Ellis, R., Piazza, F. M., Beckmann, A. M., Vergara, J., Rolf, T., Lu, L., Alter, G., Hokey, D., Jayashankar, L., Walker, R., Snowden, M. A., Evans, T., Ginsberg, A., Reed, S. G. (2018). The TLR-4 agonist adjuvant, GLA-SE, improves magnitude and quality of immune responses elicited by the ID93 tuberculosis vaccine: first-in-human trial. NPJ vaccines, 334. https://doi.org/10.1038/s41541-018-0057-5
Coler, Rhea N, et al. "The TLR-4 agonist adjuvant, GLA-SE, improves magnitude and quality of immune responses elicited by the ID93 tuberculosis vaccine: first-in-human trial." NPJ vaccines vol. 3 (2018): 34. doi: https://doi.org/10.1038/s41541-018-0057-5
Coler RN, Day TA, Ellis R, Piazza FM, Beckmann AM, Vergara J, Rolf T, Lu L, Alter G, Hokey D, Jayashankar L, Walker R, Snowden MA, Evans T, Ginsberg A, Reed SG. The TLR-4 agonist adjuvant, GLA-SE, improves magnitude and quality of immune responses elicited by the ID93 tuberculosis vaccine: first-in-human trial. NPJ Vaccines. 2018 Sep 04;3:34. doi: 10.1038/s41541-018-0057-5. eCollection 2018. PMID: 30210819; PMCID: PMC6123489.
Copy Download .nbib Format: NLM
Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease: A Scientific Statement From the American Heart Association.

Arteriosclerosis, thrombosis, and vascular biology

Reyes-Soffer G, Ginsberg HN, Berglund L, Duell PB, Heffron SP, Kamstrup PR, Lloyd-Jones DM, Marcovina SM, Yeang C, Koschinsky ML.
PMID: 34647487
Arterioscler Thromb Vasc Biol. 2021 Oct 14;ATV0000000000000147. doi: 10.1161/ATV.0000000000000147. Epub 2021 Oct 14.

High levels of lipoprotein(a) [Lp(a)], an apoB100-containing lipoprotein, are an independent and causal risk factor for atherosclerotic cardiovascular diseases through mechanisms associated with increased atherogenesis, inflammation, and thrombosis. Lp(a) is predominantly a monogenic cardiovascular risk determinant, with ≈70% to...

Cite
Reyes-Soffer G, Ginsberg HN, Berglund L, et al. Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease: A Scientific Statement From the American Heart Association. Arterioscler Thromb Vasc Biol. 2021;ATV0000000000000147doi: 10.1161/ATV.0000000000000147.
Reyes-Soffer, G., Ginsberg, H. N., Berglund, L., Duell, P. B., Heffron, S. P., Kamstrup, P. R., Lloyd-Jones, D. M., Marcovina, S. M., Yeang, C., Koschinsky, M. L. (2021). Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease: A Scientific Statement From the American Heart Association. Arteriosclerosis, thrombosis, and vascular biology, ATV0000000000000147. https://doi.org/10.1161/ATV.0000000000000147
Reyes-Soffer, Gissette, et al. "Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease: A Scientific Statement From the American Heart Association." Arteriosclerosis, thrombosis, and vascular biology vol. (2021): ATV0000000000000147. doi: https://doi.org/10.1161/ATV.0000000000000147
Reyes-Soffer G, Ginsberg HN, Berglund L, Duell PB, Heffron SP, Kamstrup PR, Lloyd-Jones DM, Marcovina SM, Yeang C, Koschinsky ML. Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease: A Scientific Statement From the American Heart Association. Arterioscler Thromb Vasc Biol. 2021 Oct 14;ATV0000000000000147. doi: 10.1161/ATV.0000000000000147. Epub 2021 Oct 14. PMID: 34647487.
Copy Download .nbib Format: NLM
Selective Host Attachment by Ixodes scapularis (Acari: Ixodidae): Tick-Lizard Associations in the Southeastern United States.

Journal of medical entomology

Ginsberg HS, Hickling GJ, Pang G, Tsao JI, Fitzgerald M, Ross B, Rulison EL, Burke RL.
PMID: 34718657
J Med Entomol. 2021 Oct 29; doi: 10.1093/jme/tjab181. Epub 2021 Oct 29.

Questing behavior and host associations of immature blacklegged ticks, Ixodes scapularis Say, from the southeastern United States are known to differ from those in the north. To elucidate these relationships we describe host associations of larval and nymphal I....

Cite
Ginsberg HS, Hickling GJ, Pang G, et al. Selective Host Attachment by Ixodes scapularis (Acari: Ixodidae): Tick-Lizard Associations in the Southeastern United States. J Med Entomol. 2021;doi: 10.1093/jme/tjab181.
Ginsberg, H. S., Hickling, G. J., Pang, G., Tsao, J. I., Fitzgerald, M., Ross, B., Rulison, E. L., & Burke, R. L. (2021). Selective Host Attachment by Ixodes scapularis (Acari: Ixodidae): Tick-Lizard Associations in the Southeastern United States. Journal of medical entomology, . https://doi.org/10.1093/jme/tjab181
Ginsberg, Howard S, et al. "Selective Host Attachment by Ixodes scapularis (Acari: Ixodidae): Tick-Lizard Associations in the Southeastern United States." Journal of medical entomology vol. (2021). doi: https://doi.org/10.1093/jme/tjab181
Ginsberg HS, Hickling GJ, Pang G, Tsao JI, Fitzgerald M, Ross B, Rulison EL, Burke RL. Selective Host Attachment by Ixodes scapularis (Acari: Ixodidae): Tick-Lizard Associations in the Southeastern United States. J Med Entomol. 2021 Oct 29; doi: 10.1093/jme/tjab181. Epub 2021 Oct 29. PMID: 34718657.
Copy Download .nbib Format: NLM
Threshold Analysis of the Cost-effectiveness of Endoscopic Ultrasound in Patients at High Risk for Pancreatic Ductal Adenocarcinoma.

Pancreas

Kumar S, Saumoy M, Oh A, Schneider Y, Brand RE, Chak A, Ginsberg GG, Kochman ML, Canto MI, Goggins MG, Hur C, Kastrinos F, Katona BW, Rustgi AK.
PMID: 34149034
Pancreas. 2021 Jul 01;50(6):807-814. doi: 10.1097/MPA.0000000000001835.

OBJECTIVES: Data from the International Cancer of the Pancreas Screening Consortium studies have demonstrated that screening for pancreatic ductal adenocarcinoma can be effective and that surveillance improves survival in high-risk individuals. Endoscopic ultrasound (EUS) and cross-sectional imaging are both...

Cite
Kumar S, Saumoy M, Oh A, et al. Threshold Analysis of the Cost-effectiveness of Endoscopic Ultrasound in Patients at High Risk for Pancreatic Ductal Adenocarcinoma. Pancreas. 2021;50(6):807-814doi: 10.1097/MPA.0000000000001835.
Kumar, S., Saumoy, M., Oh, A., Schneider, Y., Brand, R. E., Chak, A., Ginsberg, G. G., Kochman, M. L., Canto, M. I., Goggins, M. G., Hur, C., Kastrinos, F., Katona, B. W., & Rustgi, A. K. (2021). Threshold Analysis of the Cost-effectiveness of Endoscopic Ultrasound in Patients at High Risk for Pancreatic Ductal Adenocarcinoma. Pancreas, 50(6), 807-814. https://doi.org/10.1097/MPA.0000000000001835
Kumar, Shria, et al. "Threshold Analysis of the Cost-effectiveness of Endoscopic Ultrasound in Patients at High Risk for Pancreatic Ductal Adenocarcinoma." Pancreas vol. 50,6 (2021): 807-814. doi: https://doi.org/10.1097/MPA.0000000000001835
Kumar S, Saumoy M, Oh A, Schneider Y, Brand RE, Chak A, Ginsberg GG, Kochman ML, Canto MI, Goggins MG, Hur C, Kastrinos F, Katona BW, Rustgi AK. Threshold Analysis of the Cost-effectiveness of Endoscopic Ultrasound in Patients at High Risk for Pancreatic Ductal Adenocarcinoma. Pancreas. 2021 Jul 01;50(6):807-814. doi: 10.1097/MPA.0000000000001835. PMID: 34149034; PMCID: PMC8577312.
Copy Download .nbib Format: NLM
Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society.

European heart journal

Ginsberg HN, Packard CJ, Chapman MJ, Borén J, Aguilar-Salinas CA, Averna M, Ference BA, Gaudet D, Hegele RA, Kersten S, Lewis GF, Lichtenstein AH, Moulin P, Nordestgaard BG, Remaley AT, Staels B, Stroes ESG, Taskinen MR, Tokgözoğlu LS, Tybjaerg-Hansen A, Stock JK, Catapano AL.
PMID: 34472586
Eur Heart J. 2021 Dec 14;42(47):4791-4806. doi: 10.1093/eurheartj/ehab551.

Recent advances in human genetics, together with a large body of epidemiologic, preclinical, and clinical trial results, provide strong support for a causal association between triglycerides (TG), TG-rich lipoproteins (TRL), and TRL remnants, and increased risk of myocardial infarction,...

Cite
Ginsberg HN, Packard CJ, Chapman MJ, et al. Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society. Eur Heart J. 2021;42(47):4791-4806doi: 10.1093/eurheartj/ehab551.
Ginsberg, H. N., Packard, C. J., Chapman, M. J., Borén, J., Aguilar-Salinas, C. A., Averna, M., Ference, B. A., Gaudet, D., Hegele, R. A., Kersten, S., Lewis, G. F., Lichtenstein, A. H., Moulin, P., Nordestgaard, B. G., Remaley, A. T., Staels, B., Stroes, E. S. G., Taskinen, M. R., Tokgözoğlu, L. S., Tybjaerg-Hansen, A., Stock, J. K., & Catapano, A. L. (2021). Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society. European heart journal, 42(47), 4791-4806. https://doi.org/10.1093/eurheartj/ehab551
Ginsberg, Henry N, et al. "Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society." European heart journal vol. 42,47 (2021): 4791-4806. doi: https://doi.org/10.1093/eurheartj/ehab551
Ginsberg HN, Packard CJ, Chapman MJ, Borén J, Aguilar-Salinas CA, Averna M, Ference BA, Gaudet D, Hegele RA, Kersten S, Lewis GF, Lichtenstein AH, Moulin P, Nordestgaard BG, Remaley AT, Staels B, Stroes ESG, Taskinen MR, Tokgözoğlu LS, Tybjaerg-Hansen A, Stock JK, Catapano AL. Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society. Eur Heart J. 2021 Dec 14;42(47):4791-4806. doi: 10.1093/eurheartj/ehab551. PMID: 34472586.
Copy Download .nbib Format: NLM
Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society.

European heart journal

Ginsberg HN, Packard CJ, Chapman MJ, Borén J, Aguilar-Salinas CA, Averna M, Ference BA, Gaudet D, Hegele RA, Kersten S, Lewis GF, Lichtenstein AH, Moulin P, Nordestgaard BG, Remaley AT, Staels B, Stroes ESG, Taskinen MR, Tokgözoğlu LS, Tybjaerg-Hansen A, Stock JK, Catapano AL.
PMID: 34472586
Eur Heart J. 2021 Dec 14;42(47):4791-4806. doi: 10.1093/eurheartj/ehab551.

Recent advances in human genetics, together with a large body of epidemiologic, preclinical, and clinical trial results, provide strong support for a causal association between triglycerides (TG), TG-rich lipoproteins (TRL), and TRL remnants, and increased risk of myocardial infarction,...

Cite
Ginsberg HN, Packard CJ, Chapman MJ, et al. Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society. Eur Heart J. 2021;42(47):4791-4806doi: 10.1093/eurheartj/ehab551.
Ginsberg, H. N., Packard, C. J., Chapman, M. J., Borén, J., Aguilar-Salinas, C. A., Averna, M., Ference, B. A., Gaudet, D., Hegele, R. A., Kersten, S., Lewis, G. F., Lichtenstein, A. H., Moulin, P., Nordestgaard, B. G., Remaley, A. T., Staels, B., Stroes, E. S. G., Taskinen, M. R., Tokgözoğlu, L. S., Tybjaerg-Hansen, A., Stock, J. K., & Catapano, A. L. (2021). Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society. European heart journal, 42(47), 4791-4806. https://doi.org/10.1093/eurheartj/ehab551
Ginsberg, Henry N, et al. "Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society." European heart journal vol. 42,47 (2021): 4791-4806. doi: https://doi.org/10.1093/eurheartj/ehab551
Ginsberg HN, Packard CJ, Chapman MJ, Borén J, Aguilar-Salinas CA, Averna M, Ference BA, Gaudet D, Hegele RA, Kersten S, Lewis GF, Lichtenstein AH, Moulin P, Nordestgaard BG, Remaley AT, Staels B, Stroes ESG, Taskinen MR, Tokgözoğlu LS, Tybjaerg-Hansen A, Stock JK, Catapano AL. Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society. Eur Heart J. 2021 Dec 14;42(47):4791-4806. doi: 10.1093/eurheartj/ehab551. PMID: 34472586; PMCID: PMC8670783.
Copy Download .nbib Format: NLM
Showing 229 to 235 of 235 entries